Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. following a class action complaint regarding breaches of fiduciary duties by the board of directors during the specified class period [1]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Capricor, specifically those who held shares between October 9, 2024, and July 10, 2025, to discuss their legal rights [1][3]. - A class action complaint was filed against Capricor on July 17, 2025, focusing on the actions of the company's board of directors [1]. Group 2: Company Performance and Issues - The complaint alleges that Capricor misled investors regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [7]. - Capricor's statements included claims about obtaining a Biologics License Application (BLA) from the FDA, while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [7]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [7].

I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis and future trend prediction. I believe in the power of innovation to yield substantial returns and aim to provide insightful analysis on such companies here on SeekingAlpha.Analyst’s Disclosure:I/we have no stock, option or similar deriva ...

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CAPR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

Company Overview - Capricor Therapeutics (CAPR) shares increased by 5.3% to close at $6.52, with trading volume significantly higher than usual, contrasting with a 1% loss over the past four weeks [1][2]. Regulatory Update - The rise in CAPR shares is linked to a positive regulatory update regarding the Deramiocel program for Duchenne muscular dystrophy, following a Type A meeting with the FDA that provided guidance for a potential Biologics License Application [2]. Financial Expectations - The company is projected to report a quarterly loss of $0.54 per share, reflecting a year-over-year decline of 42.1%, while revenues are expected to reach $2.4 million, marking a 6.2% increase from the previous year [3]. Earnings Estimate Trends - The consensus EPS estimate for Capricor has remained stable over the last 30 days, indicating that stock price movements typically do not sustain upward trends without changes in earnings estimate revisions [4]. Industry Context - Capricor is part of the Zacks Medical - Products industry, where another company, biote Corp. (BTMD), experienced a 0.3% decline to $2.97, with a return of -11.3% over the past month [5].

Group 1 - The conference call is focused on the update of Capricor Therapeutics' DMD (Duchenne Muscular Dystrophy) program [1] - The Chief Financial Officer, A.J. Bergmann, emphasizes that forward-looking statements will be made regarding product efficacy, safety, and future R&D plans [2] - The company will discuss various aspects including revenue estimates, manufacturing capabilities, and potential regulatory developments related to their product candidates [3]

Capricor Therapeutics DMD Program Update Summary Company Overview - **Company**: Capricor Therapeutics (NasdaqCM: CAPR) - **Industry**: Biotechnology, specifically focusing on treatments for Duchenne muscular dystrophy (DMD) Key Points and Arguments Regulatory and Clinical Updates - The call provided an update on the deromyosil DMD program following a Complete Response Letter (CRL) received in July 2025, indicating ongoing discussions with the FDA [4][5] - A Type A meeting with the FDA was held, resulting in a constructive dialogue and a positive outcome regarding the path forward for deromyosil [5][10] - The pivotal trial, HOPE-three, included 105 patients, with data expected to be locked by the end of the quarter and top-line results anticipated in mid-November 2025 [6][15] Trial Design and Efficacy - HOPE-three is one of the largest placebo-controlled trials in DMD, designed to evaluate both skeletal and cardiac outcomes, with 70% of participants having cardiomyopathy at baseline [6][7] - The trial is well-powered to demonstrate statistical significance in both skeletal muscle and cardiac function, with expectations of achieving a p-value of less than 0.05 [24][27] - The FDA has agreed to review data from HOPE-three as part of the ongoing Biologics License Application (BLA), allowing for dual labeling opportunities for skeletal and cardiac muscle endpoints [10][11] Financial Position - Capricor maintains a strong financial position with over $120 million in cash and equivalents, which will support operations into 2026 and launch readiness activities [15] Patient Advocacy and Community Engagement - The company emphasized the importance of patient advocacy, showcasing testimonials from patients and their families regarding the impact of deromyosil on their lives [13][14] - Capricor is committed to working closely with the patient community and the FDA to expedite the approval process for deromyosil [14][17] Future Steps and Considerations - The timing of the PDUFA (Prescription Drug User Fee Act) date remains uncertain, with plans to submit HOPE-three data as a response to the CRL [15][20] - Discussions with the FDA regarding the potential for a major amendment or Class II resubmission are ongoing, with the aim to maintain priority review status [20][21] - The company plans to focus on the U.S. market for the immediate future, with intentions to address international opportunities later [78] Additional Important Content - The FDA's willingness to consider both skeletal and cardiac endpoints reflects an understanding of the unmet medical need in DMD, particularly regarding cardiomyopathy, which is a leading cause of mortality in the disease [12][26] - The safety profile of deromyosil remains strong, with no serious adverse events reported, reinforcing confidence in the product's therapeutic potential [32][33] - The patient population in HOPE-three is similar to that in previous trials, ensuring consistency in data and outcomes [33][44] This summary encapsulates the critical updates and insights from the Capricor Therapeutics DMD program update call, highlighting the company's strategic direction, regulatory interactions, and commitment to patient advocacy.

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. shareholders regarding alleged misconduct by certain officers and directors that may have harmed the company and its investors [1]. Group 1: Legal Investigation - The investigation focuses on potential legal claims related to misconduct by Capricor's officers and directors [1]. - Investors who held Capricor shares since before October 9, 2024, may have legal rights and are encouraged to contact Johnson Fistel for more information [2]. Group 2: Company Background - Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado [3]. - The firm has recovered over $90 million for clients and is recognized among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The law firm is encouraging long-term stockholders of Capricor who suffered losses between October 9, 2024, and July 10, 2025, to discuss their legal rights [1]. - A class action complaint was filed against Capricor on July 17, 2025, focusing on the company's disclosures regarding its lead cell therapy candidate, deramiocel [2]. - The investigation centers on whether Capricor's board misled investors about the drug's regulatory status and safety data [2]. Group 2: Regulatory Issues - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - The CRL also highlighted outstanding issues in the Chemistry, Manufacturing, and Controls section of the application [3]. Group 3: Stock Performance - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [4].

Core Viewpoint - Capricor Therapeutics, Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to a federal securities class action, with a deadline for investors to seek lead plaintiff status set for September 15, 2025 [1] Group 1 - Faruqi & Faruqi, LLP is a prominent national securities law firm with offices in New York, Pennsylvania, California, and Georgia [1]